Rare Disease Drug Launch Constraints Under Orphan Drug Regulations
Orphan drug sponsors must align regulatory choices with market-access strategy before launch.
Priya Nambiar
Priya Nambiar
8 stories
Pre-Launch Promotional Planning Under FDA Preapproval Publicity Rules
Companies can discuss investigational drugs scientifically, but not promote them as effective.
Priya Nambiar
Medicaid Managed Care Plan Engagement Strategy for Drug Brands
Drug brands must navigate three hidden layers—MCO, PBM, and formulary—to reach Medicaid patients.
Priya Nambiar
AI-Assisted Claims Tagging in Promotional Content Libraries
Regulators are cracking down on unsubstantiated AI claims with record fines and enforcement.
Priya Nambiar
Core Claims Matrix Development for New Drug Approvals
Mapping approved label claims to audience and channel prevents regulatory missteps before launch.
Priya Nambiar
FDA Draft Guidance on Directional Risk Information in Promotional Labeling
Sixteen-year-old draft guidance now drives FDA's crackdown on drug marketing risk disclosures.
Priya Nambiar
Annotated Promotional Piece Requirements for MLR Submissions
Annotation shows reviewers where every drug ad claim comes from.
Priya Nambiar
Modular content in pharma marketing: what breaks when you try to reuse approved claims across channels
Reusing approved claims across channels requires more scrutiny than most teams provide.
Priya Nambiar